Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results

Table 11 Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9^th dose of DMSA in Phase 1) and Changes in Glutathione (Dglut).

	Adjusted R²	P-value	Equation	Most significant variables
Change in PDD-BI (n = 20)	0.75	0.0006	10.25 -2.48Pb9 +0.169Sn9 +113.5Tl9 -119.1Sb9 - 1.199As9 +0.726Al9 - 0.0608DGlut	Tl9, As9, DGlut*, Pb9, Sb9*
Change in ATEC (n = 20)	0.44	0.006	9.41 -0.663Pb9 -8.80Hg9- 0.352As9	Hg9*, As9
Change in SAS (n = 18)	0.57	0.002	-1.01 +0.0985Pb9- -0.00169DGlut	Tl9*, Pb9, DGlut*
Change in ADOS (comm.. + social) (n = 20)	0.28	0.02	-1.91+00.0472As9 - 0.0877Al9	As9, Al9

This is the same analysis as Table 10, except it is for the 7-round group only, resulting in much better regression fit and much greater significance in all cases. This demonstrates that the changes in the 7-round group are much better predicted by their excretion of heavy metals and change in glutathione.